Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
|Articles|August 6, 2015

IBM To Acquire Merge for $1 Billion

IBM’s announcement that it is acquiring Merge, includes the eClinical assets of the company. While IBM led that its Watson Health platform be enhanced with data and images obtained from Merge’s medical imaging management platform, enabling Watson to “see” in an effort to unlock the value of medical images to help physicians make better patient care decisions, its press release mentioned other capabilities that IBM will gain. IBM’s Watson Health unit plans to bring together Merge’s product and solution offerings with existing expertise in cognitive computing, population health, and cloud-based healthcare intelligence offerings to:

  • Offer researchers insights to aid clinical trial design, monitoring and evaluation;

  • Help clinicians to efficiently identify options for the diagnosis, treatment and monitoring a broad array of health conditions such as cancer, stroke and heart disease;

  • Enable providers and payers to integrate and optimize patient engagement in alignment with meaningful use and value-based care guidelines; and

  • Support researchers and healthcare professionals as they advance the emerging discipline of population health, which aims to optimize an individual’s care by identifying trends in large numbers of people with similar health status. 

Read the full release.


Related to this article

© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.